Topic: Metabolex Inc.
Johnson & Johnson (JNJ) subsidiary Ortho-McNeil-Janssen has tied up new diabetes drug development deals with Diamyd and Metabolex worth a potential $1 billion combined, adding therapies for both Type 1 and Type 2 diabetes to its pipeline. Hayward, California-based Metabolex will receive ...
New oral agent has a dual mechanism of action affecting both insulin and GLP-1 release -. About Metabolex Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an ...
J&J licenses late-stage Type 2 diabetes drug from Diamyd; gets preclincal drugs from MetabolexA unit of Johnson & Johnson has partnered with a Nordic pharmaceutical to develop a potential treatment for Type 1 diabetes, the company said Monday.Sweeden's Diamyd Medical AB is ...
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from two multiple ascending dose Phase 1 clinical trials of MBX-2982. Metabolex has recently completed two additional Phase ...
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 1a clinical trial of MBX-2982. "The results of this Phase 1a clinical trial are very ...
